1922-LB: CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1RA Therapy—Real-World Data
Sign Up to like & getrecommendations! Published in 2024 at "Diabetes"
DOI: 10.2337/db24-1922-lb
Abstract: Introduction & Objective: CGM use has been shown to improve glycemic outcomes in people with diabetes. We investigated CGM use pre- and post-initiation of GLP-1 or GIP/GLP-1 RA (incretin) therapy in a T2D cohort using… read more here.
Keywords: use; cgm use; incretin therapy;
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Molecular Biosciences"
DOI: 10.3389/fmolb.2023.1170181
Abstract: Type 2 diabetes (T2D) and obesity have reached epidemic proportions. Incretin therapy is the second line of treatment for T2D, improving both blood glucose regulation and weight loss. Glucagon-like peptide-1 (GLP-1) and glucose-stimulated insulinotropic polypeptide… read more here.
Keywords: responses incretin; incretin therapy; therapy; variation responses ... See more keywords
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Sign Up to like & getrecommendations! Published in 2023 at "Molecules"
DOI: 10.3390/molecules28020751
Abstract: Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). The GLP-1R cellular signaling mechanism relevant to insulin secretion and blood glucose regulation has been extensively studied. Numerous drugs targeting… read more here.
Keywords: glp; glp signaling; incretin therapy; molecules incretin ... See more keywords